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The treatment of chronic hepatitis C virus (HCV) infection has the
potential to change signiﬁcantly over the next few years as ther-
apeutic regimens are rapidly evolving. However, the burden of
chronic infection has not been quantiﬁed at the global level using
the most recent data. Updated estimates of HCV prevalence,
viremia and genotypes are critical for developing strategies to
manage or eliminate HCV infection. To achieve this, a compre-
hensive literature search was conducted for anti-HCV prevalence,
viraemic prevalence and genotypes for all countries. Studies were
included based on how well they could be extrapolated to the
general population, sample size and the age of the study. Avail-
able country estimates were used to develop regional and global
estimates. Eighty-seven countries reported anti-HCV prevalence,
while HCV viraemic rates were available for ﬁfty-four countries.
Total global viraemic HCV infections were estimated at 80
(64–103) million infections. Genotype distribution was available
for ninety-eight countries. Globally, genotype 1 (G1) was the
most common (46%), followed by G3 (22%), G2 (13%), and G4
(13%). In conclusion, the total number of HCV infections reported
here are lower than previous estimates. The exclusion of data
from earlier studies conducted at the peak of the HCV epidemic,
along with adjustments for reduced prevalence among children,
are likely contributors. The results highlight the need for more
robust surveillance studies to quantify the HCV disease burden
more accurately.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
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drugs.new all-oral treatment options become available with a shorter
duration of treatment and more manageable side effects. With
the advent of new antivirals, boasting improved sustained viro-
logic response (SVR), HCV infection will be curable in nearly all
patients. Previous studies have shown that HCV infection can be
eliminated in the next 15–20 years with focused strategies to
screen and cure current infections as well as prevent new infec-
tions [1,2]. However, a good understanding of the number of
HCV infections is required to develop strategies to eliminate
HCV.
A number of previous studies have reported global, regional
and country level prevalence estimates of HCV infection. The
original studies conducted by the World Health Organization
(WHO) [3–7] outlined global and country level estimates. More
recent analyses provided updated prevalence estimates, but
were limited to select countries [1,8–13]. Finally, a recent
study published a revised estimate of global HCV prevalence
[14], but provided only regional estimates. Most previous glo-
bal, regional and country level analyses have failed to reconcile
estimates based on age-distribution and active infection. Most
country-level studies were conducted in the adult population;
however, when estimates were applied to a country’s entire
population, disease burden was likely overestimated. In addi-
tion, studies focused on anti-HCV (antibody positive) testing
overestimated disease burden because they include those
who have been cured, either spontaneously or through
treatment.
Knowledge of the distribution of HCV genotypes has impor-
tant clinical implications since the efﬁcacy of current and new
therapies differ by genotype. Until pan-genotypic therapies reach
the market, SVR, duration of treatment and cost of treatment will
be impacted by the genotype distribution. To date, there are no
published studies assessing HCV genotype at the global level;
however, it is understood that there are notable geographical
differences.
The objective of the current study was to conduct a compre-
hensive review of recently published literature to estimate anti-
HCV prevalence, viraemic (RNA positive) prevalence, number of
anti-HCV and viraemic infections and genotype distribution. In
addition, because more than half of the countries in the world
do not have robust studies of the HCV infected population, a sec-
ondary objective of this analysis was to extrapolate available data
to countries without prevalence estimates, to generate a global
estimate of HCV disease burden.14 vol. 61 j S45–S57
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Total HCV infections
• The total global prevalence of anti-HCV was estimated 
to be 1.6% (1.3-2.1%), corresponding to 115 (92-149) 
million past viraemic infections
• The majority of these infections, 104 (87-124) million, 
were among adults (defined as those older than 15 
years old) with an anti-HCV infection rate of 2.0% (1.7-
2.3%)
• The viraemic (RNA positive) prevalence was forecasted 
to be 1.1% (0.9-1.4%), corresponding to 80 (64-103) 
million viraemic infections
• Again, most of these viraemic infections were among 
adults who accounted for 75 (62-89) million viraemic 
infections or a viraemic prevalence of 1.4% (1.2-1.7%)
Genotype distribution
• Globally, genotype 1 was most common, accounting 
for 46% of all infections, followed by genotypes 3 
(22%), and genotypes 2 and 4 (13% each). Subtype 1b 
accounted for 22% of all infections at the global level
• There were significant variations across regions with 
genotype 1 dominating in Australasia, Europe, Latin 
America and North America (53-71% of all cases) and 
G3 accounting for 40% of all infections in Asia
• Genotype 4 was most common (71%) in North Africa 
and the Middle East, but when Egypt was excluded, it 
accounted for 34% while genotype 1 accounted for 46% 
of infections across the same regionMethodology
HCV prevalence
A comprehensive literature search was conducted in PubMed and
EMBASE, using the following search terms, respectively: ‘‘[Coun-
try Name] and [hepatitis c or hcv] and [prevalence]’’ and ‘‘[‘hep-
atitis c or hcv] and [prevalence]’’. Additional studies were
identiﬁed through manual searches of references noted in the
publications. Non-indexed government reports and personal
communication with experts within countries were also
included. Regions included in the analysis were those deﬁned
by the Global Burden of Diseases, Injuries, and Risk Factors
2010 (GBD) study [15,16].
Article titles and abstracts were reviewed for relevance and
the following data were extracted from full articles or abstracts:
anti-HCV prevalence, viraemic prevalence, studied population
(e.g., pregnant women, health care patients, screening partici-
pants, military recruits, blood donors, etc.), sample size, data col-
lection/analysis date, analysis scope (urban, rural, both and
unknown), region(s) studied (one hospital/clinic, multi hospi-
tals/clinics, city, multi city, region, multi region, national, other
and unknown) and analysis type (meta-analysis, modelling,
review article, surveillance study and other/unknown).S46 Journal of Hepatology 201Exclusion criteria
Studies in non-representative populations, (e.g., people who
inject drugs (PWID’s), haemophiliacs, minority ethnic groups, ref-
ugees, etc.), studies with a sample size of less than 1000 and stud-
ies published prior to 2000 were excluded from the analysis.
Quality score
Amulti-objective decision analysis approach [17–20] was used to
derive a score of 0–10 for each study, using three measures: how
well the reported data could be extrapolated to the general pop-
ulation, sample size and year of analysis. Supplementary Table 1
shows the 0–10 scoring system used to determine how well the
reported data could be extrapolated to the general population.
The log of the sample size was scaled as 0–10 where all studies
with a sample size greater than 10,000 received a score of 10.
Analyses conducted from 2000 to 2003 received a score of 6,
2004–2010 a score of 8 and >2010 a score of 10. A ﬁnal score
was calculated using a weighting of 60% for the extrapolation
score and 20% each for sample size and study year. For simplicity,
the 0–10 scores were converted to a data quality scale of 1–3
(study score of 0.0–<4.0 received a data quality score of 1, 4.0–
<8.0 = 2, and 8.0–10.0 = 3). Modelling studies were automatically
given a data quality score of 2. Studies without a formal assess-
ment, but deemed to be of quality for inclusion, were given a
score of 1.
Studies with the highest score were considered for the base
assumption with the exception of China, India and Nigeria
where a meta-analysis of all studies after 2000, which were
representative of the general population, were used to develop
a base estimate (see Supplementary Table 2). Blood donor
studies were excluded from base estimates because they repre-
sent healthy screened adults, but were used for low prevalence
estimates when applicable. When insufﬁcient data was avail-
able to determine a range in a country, data from neighboring
countries (or countries in the region) were used. When applica-
ble, a wide range was used for countries with a high level of
uncertainty.
The UN population database was used for the 2013 country
population by ﬁve-year age cohort [21]. The number of anti-
HCV and viraemic HCV infections was calculated by multiplying
the country’s population and the appropriate HCV prevalence.
HCV prevalence in adults
Most studies reported HCV prevalence in the adult population.
For the purpose of this exercise, the deﬁnition of adults was
assumed to include all individuals agedP15 years. When a study
included data in children, prevalence in adults was calculated
using the reported prevalence by age groups. In addition, when
studies that calculated HCV prevalence in 2013 by age group
were available [1,8,13], the adult prevalence from those studies
was considered. Countries where adjustments were made to cap-
ture only the adult population and/or HCV infection in 2013
included: Australia, Bangladesh, Belgium, Brazil, Cameroon, Can-
ada, Czech Republic, Denmark, Ethiopia, Finland, France, Ger-
many, Ireland, Luxembourg, New Zealand, Pakistan, Portugal,
Slovakia, Spain, Sweden, Switzerland, Thailand, Tunisia, United
Kingdom and Yemen.4 vol. 61 j S45–S57
Table 1. Reported HCV prevalence/infected population (adjusted for the adult population) and genotype distribution.
Genotypes 
Region/
country
Adult anti-HCV 
prevalence
Viraemic 
rate
Adult viraemic 
prevalence
Adult anti-HCV 
population 
(000)
Adult viraemic 
population 
(000)
1a 1b 1c 1 
(other)
2 3 4 5 6 Mixed/
other
Japan 1.5% 
(0.5%-2.2%)
78.1% 1.1% 
(0.4%-1.7%)
1603 
(542-2432)
1252 
(423-1899)
64.7% 34.2% 1.0%
Korea, 
Republic of
0.8% 
(0.2%-2.1%)
56.1% 0.4% 
(0.1%-1.2%)
327 
(96-868)
183 
(54-487)
3.0% 45.4% 1.3% 3.0% 45.3% 0.8% 0.2% 1.0%
Asia, Central
Armenia 5.0% 36.0% 18.0% 37.0% 3.0%
Azerbaijan 3.1% 
(1.0%-6.7%)
223 
(73-491)
Georgia 6.7% 
(5.6%-7.3%)
239 
(200-260)
3.0% 59.0% 11.0% 27.0%
Kazakhstan 3.3% 
(1.0%-6.7%)
403 
(122-818)
Kyrgyzstan 2.5% 
(1.6%-6.7%)
95 
(62-259)
Mongolia 10.8% 
(8.7%-15.6%)
69.6% 7.5% 
(6.1%-10.9%)
223 
(180-322)
155 
(125-224)
98.8% 1.2%
Tajikistan 3.1% 
(1.1%-6.7%)
161 
(58-353)
82.7% 5.8% 7.7% 3.8%
Turkmenistan 5.6% 
(1.1%-6.7%)
208 
(41-251)
Uzbekistan 11.3% 
(6.4%-13.1%)
39.2% 4.4% 
(2.5%-5.1%)
2334 
(1322-2706)
916 
(519-1062)
2.9% 64.2% 6.7% 26.0%
Asia, East
China 1.3% 
(0.4%-2.0%)
60.0% 0.8% 
(0.2%-1.2%)
14,765 
(4429-22,260)
8,859 
(2658-13,356)
1.4% 56.8% 24.1% 9.1% 6.3% 2.1%
Taiwan 4.4% 
(2.5%-6.3%)
74.5% 3.3% 
(1.9%-4.7%)
881 
(500-1261)
656 
(373-939)
2.6% 45.5% 0.7% 39.5% 1.0% 0.2% 0.5% 10.0%
Asia, South
Afghanistan 1.1% 
(0.6%-1.9%)
58.1% 0.6% 
(0.4%-1.1%)
179 
(103-310)
104 
(60-180)
Bangladesh 1.3% 
(0.2%-2.2%)
77.8% 1.0% 
(0.2%-1.7%)
1384 
(219-2444)
1077 
(171-1902)
India 0.8% 
(0.4%-1.0%)
80.8% 0.7% 
(0.4%-0.8%)
7458 
(3907-8879)
6026 
(3157-7174)
24.0% 54.4% 5.8% 0.2% 15.6%
Pakistan 6.7% 
(1.6%-10.0%)
87.4% 5.8% 
(1.4%-8.7%)
8054 
(1977-12,041)
7039 
(1728-10,524)
4.8% 1.2% 0.2% 0.8% 3.8% 79.0% 1.6% 0.1% 0.1% 8.3%
Asia, Southeast
Indonesia 0.8% 
(0.4%-2.0%)
65.7% 0.5% 
(0.3%-1.3%)
1421 
(711-3554)
934 
(467-2335)
12.5% 36.5% 12.5% 20.2% 17.4% 1.0%
Cambodia 2.3% 
(2.3%-14.7%)
75.8% 1.7% 
(1.7%-11.1%)
240 
(240-1533)
182 
(182-1162)
24.0% 20.0% 56.0%
Laos 4.4% 95.6%
Sri Lanka 46.9% 37.5% 15.6%
Myanmar 1.7% 
(1.0%-2.7%)
55.6% 0.9% 
(0.5%-1.5%)
676 
(380-1064)
376 
(211-591)
4.1% 6.9% 0.7% 39.3% 49.0%
Malaysia 1.5% 
(0.3%-7.7%)
71.9% 1.1% 
(0.2%-5.5%)
329 
(66-1691)
237 
(47-1216)
31.9% 58.6% 6.0% 3.5%
Philippines 0.9% 
(0.3%-2.0%)
609 
(214-1296)
70.7% 2.5% 26.4% 0.2% 0.2%
Thailand 2.7% 
(1.8%-3.7%)
62.7% 1.7% 
(1.2%-2.3%)
1475 
(1009-2007)
925 
(633-1259)
19.9% 13.8% 0.3% 44.2% 21.8%
Viet Nam 68.0% 12.4% 17.3% 0.7% 15.2% 54.4%
Australasia
Australia 1.7% 
(1.2%-1.8%)
74.6% 1.2% 
(0.9%-1.4%)
314 
(227-349)
234 
(169-260)
20.4% 17.2% 16.9% 5.2% 36.8% 1.9% 1.6%
New Zealand 1.9% 
(0.8%-2.2%)
67 
(29-77)
40.0% 15.0% 8.0% 35.0% 0.5% 1.0%
Caribbean
Cuba 17.0% 81.0% 2.0%
Dominican 
Republic
59.0% 3.6% 9.5% 2.4% 19.0%
Asia Pacific, High Income
(continued on next page)
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Table 1. (continued)
Genotypes 
Region/
country
Adult anti-HCV 
prevalence
Viraemic 
rate
Adult viraemic 
prevalence
Adult anti-HCV 
population 
(000)
Adult viraemic 
population 
(000)
1a 1b 1c 1 
(other)
2 3 4 5 6 Mixed/
other
Europe, Central
Albania 6.0% 50.0% 20.0% 8.0% 16.0%
Bulgaria 1.1% 
(0.3%-2.4%)
67 
(19-150)
Bosnia and 
Herzegovina
4.0% 69.3% 4.0% 21.3% 1.3%
Czech 
Republic
0.7% 
(0.2%-0.7%)
70.0% 0.5% 
(0.1%-0.5%)
60 
(18-64)
42 
(13-45)
7.7% 27.2% 31.1% 0.5% 31.1% 2.4%
Croatia 13.1% 37.4% 8.3% 2.2% 35.6% 3.4%
Hungary 0.8% 
(0.4%-2.7%)
84.6% 0.7% 
(0.3%-2.3%)
68 
(34-229)
57 
(29-194)
22.0% 58.5% 13.6% 0.9% 3.4% 1.7%
Macedonia 55.4% 44.6%
Montenegro 19.6% 35.0% 1.1% 24.7% 19.6%
Poland 0.9% 
(0.6%-1.1%)
70.0% 0.6% 
(0.4%-0.8%)
279 
(192-370)
196 
(134-259)
79.4% 0.1% 13.8% 4.9% 0.1% 1.6%
Romania 3.2% 
(2.9%-3.6%)
91.3% 2.9% 
(2.7%-3.2%)
595 
(542-654)
543 
(495-597)
5.4% 92.6% 0.8% 1.2%
Serbia 57.9% 3.7% 23.2% 6.7% 8.5%
Slovakia 1.4% 
(0.9%-2.0%)
49.2% 0.7% 
(0.4%-1.0%)
66 
(41-92)
32 
(20-45)
89.9% 1.5% 6.6% 0.5% 0.5% 1.0%
Slovenia 74.6% 56.0% 5.0% 37.8% 1.2%
Europe, Eastern
Belarus 1.3% 
(0.9%-2.9%)
69.0% 0.9% 
(0.6%-2.0%)
100 
(68-226)
69 
(47-156)
5.1% 53.8% 38.5% 2.6%
Estonia 1.0% 71.0% 3.0% 24.0%
Lithuania 2.9% 
(0.7%-3.0%)
73 
(19-77)
1.8% 59.8% 3.3% 8.7% 26.3%
Latvia 2.4% 
(1.7%-3.3%)
71.4% 1.7% 
(1.2%-2.4%)
42 
(30-58)
30 
(21-41)
1.5% 87.7% 1.5% 9.2%
Moldova 4.5% 
(2.3%-4.5%)
130 
(67-130)
Russia 4.1% 
(1.2%-5.6%)
4932 
(1395-6736)
0.9% 54.8% 8.2% 35.1% 1.1%
Ukraine 3.6% 
(0.9%-4.5%)
1385 
(333-1726)
Europe, Western
Austria 0.5% 
(0.1%-0.7%)
73.4% 0.4% 
(0.1%-0.5%)
36 
(7-51)
27 
(5-37)
20.3% 51.6% 5.0% 19.0% 4.0% 0.1%
Belgium 0.9% 
(0.1%-1.2%)
80.0% 0.7% 
(0.1%-1.0%)
86 
(11-113)
69 
(9-91)
50.4% 8.6% 6.0% 19.0% 14.0% 2.0%
Switzerland 1.5% 
(0.7%-1.8%)
105 
(48-120)
25.9% 25.9% 8.5% 29.2% 10.3% 0.1% 0.1% 0.0%
Cyprus 0.6% 
(0.5%-1.9%)
71.4% 0.4% 
(0.3%-1.3%)
5 
(4-18)
4 
(3-13)
Germany 0.6% 
(0.3%-0.9%)
66.7% 0.4% 
(0.2%-0.6%)
401 
(216-647)
267 
(144-432)
25.0% 33.0% 4.5% 6.4% 27.4% 3.3% 0.2% 0.2%
Denmark 0.7% 
(0.5%-0.7%)
62.2% 0.4% 
(0.3%-0.5%)
33 
(22-34)
21 
(14-21)
34.0% 12.0% 8.0% 43.0% 3.0%
Spain 1.7% 
(0.4%-2.6%)
68.6% 1.2% 
(0.3%-1.8%)
688 
(159-1049)
472 
(109-719)
25.5% 43.8% 3.1% 19.6% 8.0%
Finland 0.7% 
(0.6%-0.9%)
31 
(27-41)
15.0% 17.0% 16.0% 46.0% 6.0%
France 0.6% 
(0.4%-1.1%)
65.0% 0.4% 
(0.3%-0.7%)
303 
(234-578)
197 
(152-376)
14.8% 29.7% 15.4% 9.1% 19.7% 9.2% 2.0% 0.2%
United 
Kingdom
0.6% 
(0.4%-1.2%)
68.5% 0.4% 
(0.2%-0.8%)
307 
(182-624)
210 
(125-428)
24.4% 11.9% 8.8% 7.3% 43.8% 3.8%
Greece 1.9% 
(0.5%-2.6%)
178 
(47-248)
12.5% 32.6% 0.0% 7.0% 34.0% 13.9%
Ireland 1.1% 
(0.7%-1.6%)
75.0% 0.8% 
(0.5%-1.2%)
40 
(24-58)
30 
(18-44)
55.0% 4.0% 39.0% 1.0% 0.1% 1.2%
Israel 2.0% 
(0.9%-2.0%)
75.5% 1.5% 
(0.7%-1.5%)
110 
(50-110)
83 
(38-83)
69.0% 8.0% 20.0% 3.0%
Italy 2.0% 
(1.6%-7.3%)
73.3% 1.5% 
(1.2%-5.4%)
1048 
(839-3826)
768 
(615-2805)
4.2% 57.5% 3.0% 26.0% 3.6% 3.8% 0.3% 1.5%
(continued on next page)
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Table 1. (continued)
Genotypes 
Region/
country
Adult anti-HCV 
prevalence
Viraemic 
rate
Adult viraemic 
prevalence
Adult anti-HCV 
population 
(000)
Adult viraemic 
population 
(000)
1a 1b 1c 1 
(other)
2 3 4 5 6 Mixed/
other
Luxembourg 0.9% 
(0.6%-0.9%)
4 
(2-4)
55.3% 4.3% 33.6% 6.4% 0.4%
Netherlands 0.2% 
(0.1%-0.4%)
31 
(10-51)
14.8% 15.7% 18.8% 9.7% 29.3% 10.5% 1.1%
Norway 0.7% 
(0.6%-0.9%)
79.5% 0.6% 
(0.5%-0.7%)
29 
(25-37)
23 
(20-29)
28.1% 28.1% 1.8% 10.5% 28.1% 3.5%
Portugal 1.8% 
(0.5%-2.9%)
164 
(42-259)
12.4% 39.8% 2.4% 34.0% 7.0% 0.2% 4.0%
Sweden 0.7% 
(0.5%-0.7%)
77.0% 0.5% 
(0.4%-0.5%)
53 
(37-55)
41 
(29-42)
38.2% 7.0% 19.3% 33.8% 1.7%
Latin America, Andean
Peru 1.2% 
(0.4%-1.6%)
251 
(95-338)
74.0% 12.0% 2.0% 10.0% 2.0%
Latin America, Central
Colombia 5.7% 82.8% 8.5% 2.8%
Mexico 1.4% 
(1.1%-1.6%)
76.6% 1.1% 
(0.8%-1.2%)
1225 
(962-1400)
938 
(737-1072)
14.9% 32.2% 23.2% 21.8% 7.2% 0.3% 0.1% 0.3%
Venezuela 1.5% 
(0.3%-2.6%)
326 
(70-571)
43.4% 21.7% 34.4% 0.5%
Latin America, Southern
Argentina 1.5% 
(0.5%-2.5%)
80.0% 1.2% 
(0.4%-2.0%)
471 
(163-785)
377 
(131-628)
21.7% 40.9% 0.9% 24.7% 10.6% 1.3%
Chile 7.9% 72.7% 2.0% 16.5% 0.6% 0.3% 0.1%
Latin America, Tropical
Brazil 1.6% 
(1.1%-1.6%)
80.5% 1.3% 
(0.9%-1.3%)
2409 
(1704-2495)
1939 
(1371-2008)
31.0% 33.4% 0.4% 4.6% 30.2% 0.2% 0.1%
North Africa/Middle East
Algeria 1.4% 
(0.2%-2.5%)
396 
(68-708)
12.2% 57.0% 11.3% 10.0% 4.7% 0.9% 4.0%
Egypt 14.7% 
(10.3%-18.0%)
67.7% 10.0% 
(7.0%-12.2%)
8306 
(5820-10,170)
5623
(3940-6885)
2.3% 3.8% 0.8% 93.1%
Iran 0.5% 
(0.2%-1.0%)
81.8% 0.4% 
(0.2%-0.8%)
295 
(118-590)
241 
(97-483)
39.7% 12.1% 1.3% 1.4% 27.5% 0.9% 18.4%
Iraq 3.2% 
(0.3%-3.2%)
650 
(61-650)
1.4% 12.9% 17.1% 52.9% 15.7%
Jordan 40.0% 33.3% 26.7%
Kuwait 19.4% 0.7% 6.9% 54.2% 18.8%
Lebanon 25.4% 16.9% 4.9% 6.3% 45.8% 0.7%
Libya 1.2% 
(1.2%-2.3%)
53 
(53-101)
4.9% 14.6% 13.2% 14.9% 16.7% 35.7%
Morocco 1.6% 
(0.6%-1.9%)
70.9% 1.1% 
(0.4%-1.4%)
376 
(148-460)
267 
(105-326)
0.7% 75.2% 22.7% 0.7% 0.7%
Oman
Palestine 18.5% 9.8% 64.1% 7.6%
Qatar 0.9% 
(0.5%-1.5%)
17 
(9-27)
Saudi Arabia 1.5% 
(0.6%-7.3%)
51.6% 0.7% 
(0.3%-3.8%)
297 
(123-1494)
153 
(63-771)
25.9% 4.4% 2.9% 60.0% 0.3% 0.3% 6.3%
Syria 28.5% 0.8% 1.8% 59.0% 10.0%
Tunisia 1.3% 
(0.3%-2.5%)
80.0% 1.0% 
(0.2%-2.0%)
107 
(26-208)
86 
(21-166)
1.4% 82.6% 10.1% 1.4% 4.3%
Turkey 1.0% 
(0.6%-2.1%)
82.0% 0.8% 
(0.5%-1.7%)
529 
(334-1170)
434 
(274-959)
8.1% 83.7% 2.2% 4.9% 1.1%
United Arab 
Emirates
68.0% 15.0% 12.0% 3.0% 23.8% 46.2%
Yemen 2.2% 
(1.1%-3.5%)
322 
(161-511)
North America, High Income
Canada 1.1% 
(0.6%-1.3%)
74.0% 0.8% 
(0.5%-1.0%)
332 
(179-394)
245 
(133-291)
34.2% 20.1% 5.7% 15.4% 22.3% 2.3%
United 
States
1.3% 
(1.2%-2.4%)
76.9% 1.0% 
(0.9%-1.8%)
3347 
(3090-6180)
2575 
(2377-4754)
46.2% 26.3% 10.7% 8.9% 6.3% 1.1% 0.5%
(continued on next page)
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Table 1. (continued)
Genotypes 
Region/
country
Adult anti-HCV 
prevalence
Viraemic 
rate
Adult viraemic 
prevalence
Adult anti-HCV 
population 
(000)
Adult viraemic 
population 
(000)
1a 1b 1c 1 
(other)
2 3 4 5 6 Mixed/
other
Oceania
Samoa 0.2% 
(0.2%-0.9%)
0
(0-1) 
Sub-Saharan Africa, Central
Central 
African 
Republic
8.6% 8.6% 82.8%
Congo, 
Democratic 
Republic 
of the
4.3% 
(3.2%-13.7%)
110 
(82-350)
3.2% 96.8%
Congo, 
Republic 
of the
62.0%
Gabon 11.2% 
(2.1%-20.7%)
90.0% 10.1% 
(1.9%-18.6%)
115 
(22-213)
104 
(19-192)
5.7% 2.4% 91.9%
Equatorial 
Guinea
35.0% 1.7% 3.3% 60.0%
Sub-Saharan Africa, East
Ethiopia 1.3% 
(0.7%-5.8%)
676 
(378-3128)
5.6% 33.3% 50.0% 11.1%
Madagascar 1.2% 
(0.8%-1.7%)
68.0% 0.8% 
(0.5%-1.2%)
158 
(99-227)
108 
(67-154)
52.9% 47.1%
Mozambique 27.8% 22.2% 22.2% 27.8%
Sub-Saharan Africa, Southern
South Africa 1.7% 
(1.0%-2.5%)
633 
(365-923)
2.3% 22.0% 7.1% 1.2% 12.6% 12.4% 35.7% 6.7%
Zimbabwe 1.6% 
(1.0%-9.1%)
137 
(86-782)
Sub-Saharan Africa, West
Benin 3.6% 
(3.6%-12.8%)
213 
(213-756)
Burkina 
Faso
3.1% 9.4% 56.3% 15.6% 3.1% 12.5%
Côte d’Ivoire 3.3% 
(0.8%-12.8%)
393 
(95-1526)
Cameroon 11.6% 
(4.3%-29.7%)
1473 
(546-3770)
Ghana 8.7% 87.0% 4.3%
Gambia, 
The
2.1% 
(1.4%-2.9%)
21 
(14-29)
19.4% 58.1% 6.5% 16.1%
Guinea-
Bissau
1.8% 98.2%
Mauritania 1.9% 
(1.1%-10.7%)
44 (26-249)
Nigeria 8.4% 
(3.9%-12.8%)
82.2% 6.9% 
(3.2%-10.5%)
8115 
(3768-12,366)
6670 
(3097-10,165)
85.0% 15.0%
Other
Puerto Rico 2.3% 
(1.3%-4.2%)
68 
(39-125)
39.8% 27.1% 15.2% 12.1% 3.8% 1.8% 0.2%
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Anti-HCV prevalence in children (<15 years old) in the above
countries was used to estimate prevalence in children by the
World Bank regions (low income, lower middle income, upper
middle income and high income). Insufﬁcient data was available
to determine HCV prevalence by the GBD regions. The ratio of
HCV prevalence in children to adults was applied to adult HCV
prevalence in countries missing prevalence among children in
each World Bank region.S50 Journal of Hepatology 201Regional HCV prevalence
Regional prevalence estimates were applied to countries without
data to estimate the global number of anti-HCV and viraemic
positive cases. GBD regional prevalence (see Supplementary
Table 4 for a list of countries in each region) was estimated by
summing the number of HCV infections for countries in the
region (with available data) and dividing this by the sum of the
total population in the same countries. No studies were available
in the Caribbean region. A regional prevalence of 1.0% (0.2–1.6%)4 vol. 61 j S45–S57
Table 2. Regional prevalence and number of infected individuals (all ages).
Regions Anti-HCV 
prevalence
Viraemic HCV 
prevalence
Viraemic
rate
2013
population 
(millions)
Anti-HCV 
infected 
(millions)
Viraemic HCV 
infected 
(millions)
Asia Pacific, High Income 1.1% (0.5%-1.7%) 0.8% (0.4%-1.2%) 74% 182 2.0 (0.9-3.0) 1.5 (0.6-2.2)
Asia, Central 5.4% (3.5%-6.8%) 2.3% (1.5%-3.0%) 43% 84 4.5 (2.9-5.7) 1.9 (1.3-2.5)
Asia, East 1.2% (0.4%-1.8%) 0.7% (0.3%-1.1%) 60% 1434 16.6 (6.3-25.3) 10.0 (3.9-15.1)
Asia, South 1.1% (0.7%-1.5%) 0.9% (0.5%-1.2%) 81% 1650 18.8 (11.3-24.5) 15.2 (8.9-19.8)
Asia, Southeast 1.0% (0.8%-1.8%) 0.7% (0.5%-1.1%) 63% 635 6.6 (5.3-11.3) 4.2 (3.4-7.2)
Australaisa 1.4% (1.0%-1.5%) 1.0% (0.8%-1.1%) 75% 28 0.4 (0.3-0.4) 0.3 (0.2-0.3)
Caribbean 0.8% (0.2%-1.3%) 0.6% (0.1%-0.9%) 70% 39 0.3 (0.1-0.5) 0.2 (0.0-0.4)
Europe, Central 1.3% (1.1%-1.6%) 1.0% (0.9%-1.2%) 80% 119 1.5 (1.3-1.9) 1.2 (1.1-1.5)
Europe, Eastern 3.3% (1.6%-4.5%) 2.3% (1.1%-3.0%) 69% 207 6.8 (3.4-9.3) 4.7 (2.4-6.3)
Europe, Western 0.9% (0.7%-1.5%) 0.6% (0.5%-1.0%) 70% 425 3.7 (3.0-6.3) 2.6 (2.1-4.4)
Latin America, Andean 0.9% (0.4%-1.3%) 0.6% (0.3%-0.9%) 70% 57 0.5 (0.2-0.7) 0.4 (0.2-0.5)
Latin America, Central 1.0% (0.8%-1.4%) 0.8% (0.6%-1.1%) 75% 246 2.6 (1.9-3.5) 1.9 (1.4-2.6)
Latin America, Southern 1.2% (0.5%-2.1%) 0.9% (0.4%-1.6%) 79% 62 0.8 (0.3-1.3) 0.6 (0.2-1.0)
Latin America, Tropical 1.2% (0.9%-1.2%) 1.0% (0.7%-1.0%) 80% 207 2.5 (1.9-2.6) 2.0 (1.5-2.1)
North Africa/Middle East 3.1% (2.5%-3.9%) 2.1% (1.7%-2.6%) 66% 469 14.6 (11.9-18.2) 9.7 (7.8-12.1)
North America, High Income 1.0% (1.0%-1.9%) 0.8% (0.7%-1.4%) 76% 355 3.7 (3.4-6.7) 2.8 (2.6-5.0)
Oceania 0.1% (0.1%-0.6%) 0.1% (0.1%-0.4%) 69% 10 0.0 (0.0-0.1) 0.0 (0.0-0.0)
Sub-Saharan Africa, Central 4.2% (2.4%-9.2%) 2.6% (1.5%-5.5%) 61% 100 4.3 (2.4-9.2) 2.6 (1.5-5.5)
Sub-Saharan Africa, East 1.0% (0.6%-3.1%) 0.6% (0.4%-2.0%) 62% 385 3.9 (2.4-12.1) 2.4 (1.6-7.9)
Sub-Saharan Africa, Southern 1.3% (0.8%-2.5%) 0.9% (0.6%-1.7%) 69% 75 1.0 (0.6-1.9) 0.7 (0.4-1.3)
Sub-Saharan Africa, West 5.3% (2.9%-9.1%) 4.1% (2.3%-6.7%) 77% 367 19.3 (10.5-33.3) 14.9 (8.5-24.6)
Other 1.9% (1.0%-3.4%) 1.3% (0.7%-2.4%) 69% 27 0.5 (0.3-0.9) 0.4 (0.2-0.7)
Total 1.6% (1.3%-2.1%) 1.1% (0.9%-1.4%) 70% 7162 114.9 (91.9-148.7) 80.2 (64.4-102.9)
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for the range.
Genotype distribution
A literature search was conducted through PubMed and EMBASE
using the following search terms: ‘‘[hcv OR (hepatitis c)] AND
(genotype⁄ OR hepacivirus/genetics⁄[mesh])’’ and [hepatitis c
OR hcv AND (genotyp⁄)]. Studies were scored according to the
following scale: 1 = estimate without a formal published study
or small study (n <100) in a select population; 2 = large study
(n >100) in a select population; 3 = study in the general popula-
tion. Studies prior to 2000 were not excluded from this analysis,
but were only chosen as ﬁnal estimates in two countries.
Uncertainty and sensitivity analyses were conducted using
Crystal Ball, an Excel add-in by Oracle. Beta-PERT distribu-
tions were used for all uncertain inputs.Results
HCV prevalence
There were 23,248 studies identiﬁed through PubMed
(n = 11,755) and EMBASE (n = 11,493). Following the removal
of duplicates (n = 6012) and studies that did not meet inclusionJournal of Hepatology 201criteria (n = 12,335), 4901 were selected for review and inclu-
sion in the ﬁnal analysis. Eighty-seven countries had an anti-
HCV prevalence estimate that met inclusion criteria as shown
in Table 1 (Supplementary Table 2 lists data sources). These
countries accounted for 88% of the world’s adult population
and 84% of the estimated global anti-HCV population. HCV
viraemic rates were available for ﬁfty-four countries, account-
ing for 77% of the world’s adult population and 73% of the esti-
mated viraemic HCV population.
The ratio of HCV prevalence among children to adults was 54%
in low-income countries, 28% in lower-middle-income countries,
21% in upper-middle-income countries and 4% in high-income
countries. Given the high uncertainty associated with this
approach, a range of 4–54% was used for all regions. An average
viraemic rate of 50% (uncertainty interval of 50–75%) was applied
to the infected population aged <15 years [22–25].
HCV genotype distribution
The literature search identiﬁed 17,118 studies through PubMed
and EMBASE, of which 2320 were selected for review and
inclusion in the ﬁnal analysis. Genotype distribution was avail-
able for ninety-eight countries (as shown in Table 2 and Sup-
plementary Table 3), which accounted for 88% of the world’s
adult population and 83% of the estimated anti-HCV prevalent
population.4 vol. 61 j S45–S57 S51
Data quality
No data
1
2
3
A
Anti-HCV prevalence
No data
0.0% - <1.0%
1.0% - <1.5%
1.5% - <2.0%
2.0% - <5.0%
≥5.0%
B
Anti-HCV prevalence
0.0% - <1.0%
1.0% - <1.5%
1.5% - <2.0%
2.0% - <5.0%
≥5.0%
C
Viraemic prevalence
No data
0.0% - <0.75%
0.75% - <1.25%
1.25% - <1.75%
1.75% - <2.5%
≥2.5%
D
Viraemic prevalence
0.0% - <0.75%
0.75% - <1.25%
1.25% - <1.75%
1.75% - <2.5%
≥2.5%
E
Viraemic infected
0 - 100,000
100,001 - 500,000
500,001 - 1,000,000
1,000,001 - 5,000,000
≥5,000,001
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Fig. 2. Genotype distribution by region.
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JOURNAL OF HEPATOLOGYThe evolution of the analysis is shown in Fig. 1. The quality
scores of the anti-HCV studies in Fig. 1A denotes how well the
reported anti-HCV prevalence could be extrapolated to the gen-
eral population. The anti-HCV prevalence for countries with
reported data is shown in Fig. 1B while Fig. 1C includes regional
estimates for countries without reported data. The reported
viraemic rates for countries with data are shown in Fig. 1D.
A regional average was applied to countries without data to gen-
erate Fig. 1E (viraemic prevalence among adults for all countries).
Fig. 1F summarizes the number of viraemic HCV infections (all
ages), in each country. A detailed list of data sources and quality
scores is presented in the Supplementary Tables 2 and 3.
Anti-HCV prevalence, viraemic prevalence and genotype distribu-
tion for the countries missing studies were extrapolated from theFig. 1. Reported HCV prevalence and infections among adults. (A) Anti-HCV preva
prevalence – adults (reported and estimated). (D) Viraemic prevalence – adults (with repo
Number of viraemic HCV infections – all ages.
Journal of Hepatology 201regional estimates. Fig. 2 illustrates the genotype distribution by
region.
The global prevalence of anti-HCV was estimated at 2.0% (1.7–
2.3%) among adults and 1.6% (1.3–2.1%) for all ages correspond-
ing to 104 (87–124) million and 115 (92–149) million infections,
respectively. The viraemic prevalence was 1.4% (1.2–1.7%) among
adults and 1.1% (0.9–1.4%) in all ages corresponding to 75 (62–
89) million and 80 (64–103), respectively. Table 2 summarizes
the forecasts for all ages by GBD regions while Fig. 3 shows the
total number of anti-HCV and viraemic infections among adults,
children and the total population.Discussion
Total global viraemic HCV infections were estimated at 80 (64–
103) million infections. Thirty-one countries accounted for 80%
of total viraemic infections as shown in Fig. 4, in the order of their
contribution. China, Pakistan, Nigeria, Egypt, India, and Russia
together accounted for more than half of total infections. The
uncertainties that account for >90% of the estimated variance of
64–103 million viraemic infections are shown in Fig. 5. The
uncertainty in viraemic prevalence in Nigeria, China and Pakistan
account for over 50% of the observed variance, followed by the
uncertainty in ratio of HCV prevalence among children to adults.
The sensitivity analysis shows that the uncertainties in preva-
lence estimates in African countries (Ethiopia, Cameroon and
Democratic Republic of Congo) can lead to a higher estimated
number of viraemic infections if the actual prevalence is closer
to the upper end of our range.
In this analysis, special carewas taken not to over-rely on avail-
able data but instead to focus on analysing relevant data. For exam-
ple, HCV prevalence among blood donors is available in manylence quality scores. (B) Anti-HCV prevalence – adults (reported). (C) Anti-HCV
rted viraemic rate). (E) Viraemic prevalence – adults (reported and estimated). (F)
4 vol. 61 j S45–S57 S53
24
6
8
10
12
14
16
0T
ot
al
 v
ire
m
ic
 in
fe
ct
io
ns
, a
ll 
ag
es
 (m
ill
io
ns
)
Ch
ina
Pa
kis
tan
Ni
ge
ria
Eg
yp
t
Ind
ia
Ru
ss
ia
Un
ite
d S
tat
es
Br
az
il
Co
ng
o, 
Re
pu
bli
c o
f th
e
Ja
pa
n
Ca
me
roo
n
Ba
ng
lad
es
h
Uz
be
kis
tan
Th
ail
an
d
Gh
an
a
Ind
on
es
ia
Uk
rai
ne
Me
xic
o
Ita
ly
Ni
ge
r
Et
hio
pia
Ta
iw
an
Vie
tna
m
Bu
rki
na
 Fa
so
Se
ne
ga
l
Ch
ad
Ro
ma
nia Ma
li
An
go
la
So
uth
 Af
ric
a
Sp
ain
Fig. 4. Countries accounting for 80% of the total viraemic HCV infections.
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Fig. 5. Sensitivity analysis of global viraemic infections – all ages.
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Journal of Hepatology Update: Hepatitis Ccountries and represents an attractive data source due to the large
sample size. However, this population often corresponds to
healthy screened adults who are not representative of the total
population. Other studies have derived a national estimate by
applying a gross-up factor to HCV prevalence among blood donors
[12]. All attempts to replicate national estimates in countries that
reported both a national surveillance study and blood donor data
were unsuccessful. In this work, HCV prevalence among blood
donors was used as a low-end estimate for the uncertainty
analysis.
There are also numerous studies in high-risk populations (e.g.,
PWIDs, haemodialysis patients, cancer patients, paid blood
donors, etc.). Again, these populations were excluded, as they
were not representative of HCV prevalence in the general popu-
lation. Injection drug users are a major source of new infections
in Europe and North America and exclusion of studies in PWIDs
would suggest that we are underestimating the total number of
infections. Previous publications estimated 10.0 million (6.0–
15.2 million) PWIDs worldwide may be anti-HCV positive
[26,27]. Some part of this population was already included in
the country prevalence estimates (e.g., Australia), while the
uncertainty range in other countries (e.g., US) was meant to take
into account populations not captured in the base estimates. WeS54 Journal of Hepatology 201were unable to determine the exact overlap between the
reported number of HCV infections among PWIDs and the total
number of infections reported here. It is possible that we are
underestimating the total number of infections – at maximum
by 10 million. However, the PWID population not captured in
the base estimate should be within the uncertainty range pre-
sented here.
Finally, there are numerous studies reporting HCV prevalence
that were published prior to 2000, which were also excluded. A
number of analyses have shown that HCV prevalence has been
declining in many countries [13,28–30,56,57]. This decrease was
due to a number of factors – increasedmortality due to the infected
population aging, a reduction in the new infections due to the
implementation of blood supply screening and a drop in high-risk
behaviour in the early 1990s as the transmission of HIVwas better
understood. It is important to note that treatment has had a
minimal impact on the total number of infections. With the
exception of a few countries (e.g., France) [8,13], treatment
and SVRs have been too low to make a large impact on HCV
prevalence so far.
The total number of HCV infections reported here are lower
than previous estimates [5,12,14]. As shown in Supplementary
Fig. 1, most of the differences can be explained by prevalence
estimates in a two regions: South Asia and East Asia. Fig. 4 high-
lights that the majority of HCV infections at a global level are
accounted for by a few countries. India accounts for more than
75% of the population in the South Asia region and estimates
for its HCV prevalence have been historically inﬂuenced by stud-
ies in the Punjab region [31]. While this region has a high HCV
prevalence, it represents less than 3% of India’s total population.
Studies in other regions of India have shown a signiﬁcantly lower
HCV prevalence [32–34]. In this work, a meta-analysis was used
to estimate a national average of 0.84% (0.44–1.0%) vs. 1.5% [5]
and 3.4% (regional estimate) [14] in previous studies.
Similarly, China accounts for over 96% of the population in
East Asia. There are a number of studies among commercial blood
and plasma donors that showed a very high HCV prevalence [35–
37]. However, paid blood donation is no longer common practice
in China and studies in ﬁrst time blood donors show that anti-
HCV infections were less than 1% [38–40]. With a few exceptions,4 vol. 61 j S45–S57
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prevalence studies in hospital patients [41] and rural/urban pop-
ulations [42–45] all show a relatively low HCV prevalence. In this
study, a meta-analysis (excluding studies in blood donors) was
used to estimate a national prevalence of 1.3% (0.39–1.96%) vs.
2.2% [5] and 3.7% (regional estimate) [14] in previous analyses.
The present work estimates a higher prevalence in Sub-Saha-
ran West Africa where Nigeria accounts for close to half of the
region’s population. As shown in Supplementary Table 2, a
meta-analysis of non-blood donor studies in Nigeria resulted in
an anti-HCV prevalence of 8.4% (3.9–12.8%) as compared to
2.1% [5] and 2.8% (regional estimate) [14] in previous work.
There are other minor differences between this study and pre-
vious work. One study applied the anti-HCV prevalence to the
total population [5]. According to the United Nations [46], 25%
of the world’s population was aged <15 years in 2013. There is
ample evidence that prevalence in this population is a fraction
of the adult population [47–52] and a higher percentage of this
population spontaneously clears the virus [22–24]. Other studies
applied the HCV prevalence to the adult population (P15) with-
out further adjustments for the younger ages [12].
This analysis reports the total number of viraemic infections.
The average viraemic rate was estimated at 70% (all ages),
although it varied between 43% in Central Asia to 81% in South
Asia. Some countries that reported high anti-HCV prevalence also
had a low viraemic rate. The most vivid example was a study in
Poland [53], which found an anti-HCV prevalence of 1.9% with
a viraemic rate of 31% (a viraemic prevalence of 0.6%). A separate
study in the same country used conﬁrmatory antibody testing
and found an anti-HCV prevalence of 0.86% [54] with the same
viraemic prevalence of 0.6% [unpublished data]. This example
highlights the need to study viraemic infections since some his-
torically high antibody prevalence estimates may have had a cor-
responding low viraemic rate.
Globally, genotype 1 (G1) accounted for 46% of all anti-HCV
infections among adults making it the most common, followed
by G3 (22%), G2 (13%), G4 (13%), G6 (2%), and G5 (1%). Undeﬁned
or combination genotypes accounted for 3% of the total HCV infec-
tions. Genotype 1b was the most common sub-type, accounting
for 22% of all infections. However, signiﬁcant regional, country
and local variations existed. Infections in North America, Latin
America, and Europe were predominately G1 (62–71%) with G1b
accounting for 26%, 39%, and 50% of all cases respectively. North
Africa and the Middle East had a large G4 population (71%), which
was attributable to the high prevalence of G4 in Egypt. When
Egypt was excluded, genotype 4 accounted for 34% of all infec-
tions and the genotype distribution of this region was dominated
by G1 (46%). Asia was predominately G3 (39%) followed by G1
(36%), largely driven by the HCV infections in India and Pakistan.
G1b accounted for 25% of all infections in this region. In Austral-
asia, G1 dominated (53%), followed by G3 (39%). G1b was present
in 16% of cases. HCV genotypes by subregions are shown in Fig. 2.
There were a number of limitations worth noting. PubMed
and EMBASE do not capture all sources for non-English language
studies, thus, some studies may not have been identiﬁed. Efforts
were made to include non-English publications and government
reports. Personal communications with local experts were also
used to capture data published in sources not listed in the above
databases. In addition, data was not available for all countries (as
shown in Fig. 1B and D) and regional estimates had to be used for
many countries. In regions where limited data was available, the
regional average was highly dependent on data from very fewJournal of Hepatology 201countries and countries with a high population. For example,
the Asia-Central viraemic rate estimate was based on estimates
from Uzbekistan (viraemic rate of 39%) and Mongolia (viraemic
rate of 70%), yet the regional estimate was heavily weighted by
Uzbekistan due to its much larger population. Data from addi-
tional countries in the region would be helpful in minimizing this
type of bias.
Another limitation was the availability of robust epidemiology
studies at the national level. Among the eighty-seven countries
with an anti-HCV prevalence estimate, only 16 (18%) received a
quality score of 3. High quality studies were not limited to
high-income countries. In fact, more than 50% of these studies
were in low-income or upper middle-income countries. The char-
acteristics consistent among these sources included the follow-
ing: random sampling strategy in the general population,
inclusion of participants from multiple cities or ‘‘regions’’ (e.g.,
districts, states, provinces, etc.) and a sample size >10,000,
although a well conducted study in a small country with a sample
size of >1500 could be sufﬁcient. In addition, 75% of these studies
were published after 2010 and more than 80% reported a virae-
mic rate. Alternatively, 36 (41%) studies received a quality score
of 1. These sources were generally conducted in a select
population (e.g., pregnant women, health care workers, etc.)
within one setting (e.g., hospital, clinic, city, etc.). The authors
acknowledge that robust studies with large sample sizes are
costly and take time to complete; however, these types of
studies are much more dependable for estimating the burden of
HCV at a national level.
In the absence of better data, this analysis assumed that HCV
prevalence remained constant from the time of the study to 2013.
In fact, other studies have suggested that HCV prevalence may be
declining with time in some countries [28,29,56,57]. Similarly,
the viraemic rate was applied to the 2013 estimates. However,
we expect that the impact of a change in viraemic rate would
be small since treatment rates have remained low in most coun-
tries [8,13]. In addition, not all studies reported the age of partic-
ipants. The reported prevalence was applied to the adult
population; thus, we may be underestimating the true number
of infections if individuals younger than 15 years old were
included (a lower prevalence is typical when children are
included).
There were relatively few studies that included children and
several studies used a broad range (e.g., age cohort 0–20) to
describe prevalence in younger populations. In this study, care
was taken to use a different ratio of HCV prevalence among chil-
dren to adults in different regions to provide a more accurate
estimate. Our analysis found that HCV infection among children
is highest in low-income countries and lowest in high-income
countries, presumably due to the different risk factors for new
infections (injection drug use in high-income countries vs. noso-
comial infections in low-income countries). To examine the
impact of uncertainty in this population, a wide range was used
(a range 4–54% for the ratio of HCV prevalence among children
to adults in all regions). The impact of this population on the
global estimate appears to be small. Sensitivity analysis
(Fig. 5) showed that we could be underestimating the total
number of viraemic infections by 5 million if the actual rate
was set to the high end of the uncertainty range for all
countries/regions.
Another limitation was the way national prevalence was
reported. Some studies reported the HCV prevalence in a country4 vol. 61 j S45–S57 S55
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based on the sampling in the study. When data was provided, an
attempt was made to estimate a more reﬁned HCV prevalence
estimate by using age speciﬁc prevalence rates and the
country’s population by age cohort. This minimized any error
due to a different age distribution in the general and studied pop-
ulation. However, not all countries provided age-speciﬁc preva-
lence rates.
In light of new therapies, many countries are examining
requirements to eliminate HCV infection within their borders.
The current study suggests that this task might be less daunting
since recent data suggest that there are fewer HCV infections
than were previously reported. For years, anti-HCV prevalence
has been used as a proxy for the HCV infection rate. As cure rates,
and potentially treatment rates, increase, measurement and
reporting of viraemic prevalence will be required to measure
and track the impact of HCV elimination strategies. A number
of countries are attempting to quantify the proportion of HCV
prevalence within the country due to immigration. Researchers
are cautioned to use the data presented here without any
adjustments. Our research (to be published) has shown that
the average age among immigrants, in most countries, is
approximately 30 years of age, leading to a lower HCV infection
rate than estimated in the broad population in the country of
origin.
The data shown here represent the most recent estimates of
HCV infection and genotype distribution. The HCV prevalence
estimates are generally lower than in previous work. This is
alarming as it may suggest that HCV infection is more deadly
than previously thought since the number of observed deaths
[55] is the consequence of a lower number of viraemic infections.
The prevalence and genotype estimates will need to be updated
as new data become available and will likely change signiﬁcantly
with the adoption of highly efﬁcacious therapies in the coming
years. Previous research has shown that although the total num-
ber of infections may be declining in some countries, the disease
burden of HCV is expected to increase [1,13,28,29]. The results
highlight the need for more robust surveillance studies to quan-
tify the HCV disease burden more accurately.Financial support
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